Head to Head Comparison: Neuphoria Therapeutics (NASDAQ:NEUP) & Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Entrada Therapeutics and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics -4,057.98% -64.00% -50.49%
Neuphoria Therapeutics N/A -38.31% -28.92%

Insider and Institutional Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Entrada Therapeutics and Neuphoria Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 1 2 4 0 2.43
Neuphoria Therapeutics 1 2 0 0 1.67

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 248.72%. Neuphoria Therapeutics has a consensus target price of $7.00, indicating a potential upside of 174.51%. Given Entrada Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Neuphoria Therapeutics.

Risk & Volatility

Entrada Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Earnings & Valuation

This table compares Entrada Therapeutics and Neuphoria Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entrada Therapeutics $25.42 million 7.84 -$143.75 million ($3.84) -1.33
Neuphoria Therapeutics $1.17 million 11.79 -$13.45 million ($6.22) -0.41

Neuphoria Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.